Jackson Creek Investment Advisors LLC Makes New Investment in Guardian Pharmacy Services, Inc. $GRDN

Jackson Creek Investment Advisors LLC acquired a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) during the 4th quarter, Holdings Channel reports. The firm acquired 14,578 shares of the company’s stock, valued at approximately $439,000.

Other institutional investors have also modified their holdings of the company. CSM Advisors LLC raised its stake in shares of Guardian Pharmacy Services by 40.9% in the 3rd quarter. CSM Advisors LLC now owns 135,665 shares of the company’s stock valued at $3,559,000 after purchasing an additional 39,360 shares in the last quarter. Aristotle Capital Boston LLC raised its stake in shares of Guardian Pharmacy Services by 58.5% in the 3rd quarter. Aristotle Capital Boston LLC now owns 649,463 shares of the company’s stock valued at $17,035,000 after purchasing an additional 239,790 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in shares of Guardian Pharmacy Services by 5.6% in the 3rd quarter. TimesSquare Capital Management LLC now owns 860,173 shares of the company’s stock valued at $22,562,000 after purchasing an additional 45,950 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Guardian Pharmacy Services by 274.9% in the 4th quarter. SG Americas Securities LLC now owns 19,017 shares of the company’s stock valued at $572,000 after purchasing an additional 13,945 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Guardian Pharmacy Services in the 4th quarter valued at about $3,489,000.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GRDN shares. Jefferies Financial Group started coverage on shares of Guardian Pharmacy Services in a research note on Monday, March 30th. They issued a “buy” rating and a $44.00 target price on the stock. Oppenheimer raised their price objective on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Bank of America assumed coverage on Guardian Pharmacy Services in a research note on Monday, April 27th. They set a “buy” rating and a $42.00 price objective on the stock. Raymond James Financial restated an “outperform” rating and set a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Finally, Wall Street Zen cut Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Guardian Pharmacy Services has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Guardian Pharmacy Services Price Performance

Shares of GRDN opened at $39.11 on Thursday. The business’s fifty day moving average price is $37.10 and its 200 day moving average price is $33.15. Guardian Pharmacy Services, Inc. has a 12-month low of $19.17 and a 12-month high of $41.36. The stock has a market capitalization of $1.95 billion, a PE ratio of 47.12, a price-to-earnings-growth ratio of 2.53 and a beta of 0.09.

Guardian Pharmacy Services (NYSE:GRDN) last issued its earnings results on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The company had revenue of $336.60 million during the quarter, compared to the consensus estimate of $329.89 million. During the same period in the previous year, the firm posted $0.22 earnings per share. Guardian Pharmacy Services’s quarterly revenue was up 2.2% compared to the same quarter last year. As a group, research analysts anticipate that Guardian Pharmacy Services, Inc. will post 1.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Guardian Pharmacy Services news, Director William E. Bindley sold 3,570,677 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $105,977,693.36. Following the completion of the transaction, the director directly owned 4,469,316 shares in the company, valued at $132,649,298.88. The trade was a 44.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Ackerman sold 1,103,364 shares of Guardian Pharmacy Services stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $29.68, for a total value of $32,747,843.52. Following the completion of the transaction, the director owned 345,123 shares of the company’s stock, valued at approximately $10,243,250.64. The trade was a 76.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,726,405 shares of company stock valued at $288,679,700 over the last 90 days. 32.96% of the stock is owned by corporate insiders.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.